Market Driver Insights: The Impact of Recent Advances on the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) for Formulations Market

The pharmaceutical contract development and manufacturing organization (CDMO) sector for formulations is poised for significant advancement in the coming years. With technological innovations and increasing outsourcing trends, this industry is set to expand rapidly, offering new opportunities for growth and collaboration between pharmaceutical companies and CDMOs. Let's explore the market's expected value, key players, emerging trends, and important segments shaping its trajectory.

Pharmaceutical CDMO for Formulations Market Size Set to Expand by 2030
The pharmaceutical CDMO market for formulations is forecasted to experience swift growth, reaching a valuation of $90.76 billion by 2030. This expansion represents a compound annual growth rate (CAGR) of 10.6%. Key drivers of this growth include advancements in custom peptide synthesis technologies, scaling up of commercial GMP manufacturing, and increasing outsourcing activities to contract research organizations (CROs) and small to medium enterprises (SMEs). Moreover, strategies focused on lifecycle management and process optimization, alongside rising demand for clinical and preclinical peptide API manufacturing, are contributing significantly to the market's development. Important trends to watch include the growing outsourcing of peptide API production, the rise in GMP-grade manufacturing to support clinical and commercial supplies, and expanding pipelines for peptide therapeutics among pharmaceutical firms.

Download a free sample of the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25876&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Factors Fueling Growth in the Pharmaceutical CDMO Market
One of the main factors propelling the growth of the pharmaceutical CDMO for formulations market is the increasing reliance on outsourced manufacturing and development services by pharmaceutical companies. This shift allows companies to reduce operational costs, access specialized expertise, and speed up product development timelines.

Another important influence is the expansion of commercial-scale GMP manufacturing capacity. This facilitates the production of high-quality clinical and commercial drug supplies, meeting stringent regulatory standards and growing demands from pharmaceutical clients. The focus on process optimization and lifecycle management further enhances manufacturing efficiencies and product quality, supporting sustained market growth.

View the full pharmaceutical contract development and manufacturing organization (cdmo) for formulations market report:
https://www.thebusinessresearchcompany.com/report/pharmaceutical-contract-development-and-manufacturing-organization-cdmo-for-formulations-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Industry Players in the Pharmaceutical CDMO for Formulations Sector
The pharmaceutical contract development and manufacturing organization market for formulations features several key players that dominate the landscape. These include Thermo Fisher Scientific Inc., Lonza Group, Catalent Inc., WuXi Biologics, Samsung Biologics, Recipharm AB, Siegfried Holding AG, Evonik Industries AG, Almac Group, Aenova Group, Piramal Pharma Limited, Cambrex, Jubilant Pharmova Limited, CordenPharma, Altasciences, Hovione, Aurigene Pharmaceutical Services Ltd., DPT Laboratories Ltd., CARBOGEN AMCIS, Biopharma Group, LGM Pharma, and Aarti Pharmalabs Limited.

Recent Strategic Acquisition Enhances Jabil's Pharmaceutical Capabilities
In February 2025, Jabil Inc., a US-based provider of engineering, manufacturing, and supply chain solutions, took a significant step by acquiring Pharmaceutics International Inc. (Pii). Though the financial details were undisclosed, this acquisition strengthens Jabil's pharmaceutical manufacturing and development portfolio by adding Pii's expertise in aseptic filling, lyophilization, and oral solid dose production. Through this move, Jabil enhances its position in parenteral drug delivery and broadens its end-to-end support across both clinical and commercial manufacturing stages. Pharmaceutics International Inc. (Pii) specializes as a pharmaceutical contract development and manufacturing organization offering formulation development services ranging from injectable to oral drug forms.

Emerging Innovations Shaping the Pharmaceutical CDMO Market
Cutting-edge developments are redefining the pharmaceutical CDMO for formulations space, with many companies focusing on biologic formulation platforms. These platforms are designed to improve drug stability and speed up the time-to-market for complex biologic therapies by optimizing factors such as pH, excipients, and delivery methods, thereby enhancing bioavailability and safety throughout the product life cycle.

A notable example occurred in June 2025, when China-based WuXi Biologics introduced WuXiHigh 2.0, an advanced high-concentration biologic formulation platform. This technology supports protein concentrations up to 230 mg/mL, exceeding the current FDA-approved limit of 200 mg/mL, while reducing viscosity by as much as 90% through proprietary excipient blends and high-throughput instrumentation. It addresses challenges like viscosity and aggregation, improving injection efficiency, patient compliance, and manufacturing outcomes across clinical and commercial phases.

Key Segments Defining Market Dynamics for Pharmaceutical CDMOs
The pharmaceutical CDMO for formulations market is categorized across several major segments that illustrate the diversity of products and end-users:

1) Dosage Form: Including oral solids, oral liquids, injectables, topicals, inhalation products, transdermal patches, and other dosage types.
2) Therapeutic Area: Covering oncology, cardiology, central nervous system disorders, gastroenterology, infectious diseases, and endocrinology.
3) End-User: Comprising pharmaceutical companies, biopharmaceutical companies, and other end-users.

Further breakdowns provide deeper insight:
- Oral solids include tablets, capsules, granules, powders, and modified-release formulations.
- Oral liquids cover syrups, suspensions, solutions, emulsions, and elixirs.
- Injectables involve vials, ampoules, prefilled syringes, lyophilized injections, and injectable emulsions.
- Topicals encompass creams, ointments, gels, lotions, and foams.
- Inhalation products consist of metered dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizer solutions, nasal sprays, and inhalation capsules.
- Transdermal and patches include matrix patches, reservoir patches, drug-in-adhesive patches, microneedle patches, and iontophoretic patches.
- Other dosage forms cover suppositories, ophthalmic preparations, buccal tablets, sublingual tablets, and implants.

Outlook on Regional Growth and Market Expansion
While North America currently leads the pharmaceutical CDMO for formulations market in terms of size, the Asia-Pacific region is expected to experience the fastest growth over the coming years. This global view includes assessments across regions like Western Europe, Eastern Europe, South America, and the Middle East and Africa, providing a broad perspective on ongoing and emerging market trends.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.